GUIA DE SEGUIMIENTO FARMACOTERAPEUTICO SOBRE DIABETES PDFGUIA DE SEGUIMIENTO FARMACOTERAPEUTICO SOBRE DIABETES PDF
que la mortalidad a largo plazo esté relacionada sobre todo con la recidiva de la enfermedad actuaciones en una guía de seguimiento del paciente trasplantado. . documento recoge recomendaciones farmacoterapéuticas, de autocuidado, de . de las guías. • Algunos pacientes pueden comenzar con una diabetes de. Efectividad del seguimiento farmacoterapéutico en diabéticos tipo 2 clínica, se obtuvo información sobre medicamentos antidiabéticos utilizados, dosis, .. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Objetivos: Realizar un seguimiento farmacoterapéutico y educar a pacientes conocimiento sobre la menopausia y la THR en pacientes menopaúsicas. Keywords: Hormone . ministerial que generará Guías Clínicas y tratará . stock de éste por el laboratorio que los produce. Diabetes. 38%. Depresión.
|Published (Last):||3 June 2009|
|PDF File Size:||20.20 Mb|
|ePub File Size:||2.9 Mb|
|Price:||Free* [*Free Regsitration Required]|
This finding warrants conducting a more profound study of the impact expected of pharmacotherapeutic monitoring on the cost of healthcare. On the other hand, hypertension and DM are the most important risk factors that lead to deterioration in renal function, because the kidney is one of the target organs in these conditions; at the same time, together they will increase the cardiovascular risk 22 The primary etiology in all CKD patients appears in Figure 1.
There no important variations or statistically significant differences in HbA1c values for patients in the intervention and control groups at the end of the study; although there was a reduction in values of glycated hemoglobin in the intervention group, making it convenient to suggest a similar study with a bigger population sample and a better control of losses.
Direct health care costs of diabetic patients in Spain. Initial HbA1c mean was 7. The Ethics Committee of the centre approved the study.
This study presented a series of difficulties worth describing because they may be useful for those who may implement pharmacotherapeutic monitoring, such as: It was noted that the mean ratio average per patient for the patients in the control group was 1. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, El cociente medio del costo por paciente en el grupo control fue 1.
NOM are classified into problems of necessity, effectiveness, and safety; necessity Guiia include untreated health problems and the effects farmqcoterapeutico unnecessary medications, effectiveness NOM include the quantified and non-quantified ineffectiveness, and safety NOM include quantified and non-quantified lack of safety 9 Table 2 shows the NOM identified, with those relating to effectiveness being the most frequent That is why Pharmaceutical Care should include SOPs structured by criteria reached by consensus to conduct Pharmaceutical Care Practice, which will enable to prevent, identify and solve any negative outcomes in patients that are associated with medication.
Because the statistics for hypothesis tests were not significant, we opted for a bivariate analysis for the quantitative parameters via hazard ratios. Using the random number table method, we assigned the groups in random and stratified manner; in the intervention group, who had pharmacotherapeutic sguimiento for 18 months; and in the control group, who were merely interviewed at the beginning and at the end of the study. The selection and justification for use of medications was assessed; this way, Necessity NOMs were determined.
Analysis per healthcare insurance carrier revealed that the difference in the mean ratio of the direct cost was in the range of 1.
Seguimiento farmacoterapéutico en pacientes con insuficiencia renal crónica
During each of the interviews of the patients in the intervention and control groups, we identified the NOM and the possible causes. La HbA1c inicial tuvo un promedio de 7. The authors manifest and declare having no conflict of interest. Pharmacotherapeutic Monitoring PTM is defined as the professional practice in which the pharmacist assumes responsibility for the needs of the patient related to medications. Only 39 patients The sample size was estimated sibre the comparison of two proportions.
Therefore, these points must be emphasized at the time of treating their basal conditions.
Universidad de Granada Grupo de Investigación en Atención Farmacéutica [WorldCat Identities]
A population-based survey in an urban community. Due to the reduction in the glomerular filtration rate, the excretory and waste depurative function is reduced; this situation can affect the drug kinetics and dynamics, and this can have an impact on pharmacological treatment, an increase in the intensity and therapeutic effect, such as adverse events Along with other studies, during the initial interview, we found co-morbidities frequently associated to diabetes, such as hypertension The descriptive analysis revealed the following: Dose readjustments were conducted because treatments were not effective and safe, through pharmaceutical intervention.
On the other hand, there was an increase in the haemoglobin levels in the optimal group. Rev Cubana Farm ; 41 2 Cochrane Database Syst Rev.
Universidad de Granada Grupo de Investigación en Atención Farmacéutica
The main reasons for this are:. It was calculated that the among the main antidiabetic medications fatmacoterapeutico [Defined Daily Dose DDD ] glibenclamide represented 0. Glucose intolerance in Colombia. Los pacientes de ambos grupos tomaban en promedio 6. There is evidence in different countries around the world that the lack of NOM detection and solution may lead to additional costs in the healthcare system.
The need to schedule home visits requiring greater investment of time when the patient’s health status does not permit attending the healthcare facility. Like a snake in the grass. In developed nations as in developing nations, effectiveness of the therapy measured by controlling HbA1c figures ranges between There is also evidence in that the results of pharmaceutical care may lead to reduced utilization of healthcare services and to a lower number of medications prescribed Patients with type-2 diabetes mellitus, affiliated to the contributive regime of two EPS, who had continuity in antidiabetic treatment in the three months prior, defined by attendance to medical control and request for dispensing of normoglycemiant gui these patients were over 18 years of age and accepted to participate in the study.
Mean age was The NOMs with the highest prevalence were those for Non-Quantitative Insecurity; therefore, these represent a highly prevalent problem. Diabetes in the Americas. Many of these difficulties came about because of the lack of support and commitment with the study from personnel in the participating healthcare insurance carriers.
Upon changes in medication, a new condition status farmacoteeapeutico established, which also evaluated the acceptance or non-acceptance of the physician’s pharmaceutical recommendations. As the incidence of type 2 diabetes escalates, new developments offer hope for better treatments, reports. Those with a lower proportion were: The mean cost per patient in controls was 1.
Through an interview and evaluation of medical records, we obtained information about antidiabetic medications used, doses, other medications, along with Hemoglobin A1c level, arterial pressure, serum low-density lipoprotein cholesterol level, nephropathy screening, retinal screening, foot exams in the wobre year and problems associated with medication use by means of the DADER method Negative Outcomes Associated with Medication NOM.
The inability by patients to excrete drugs that are eliminated through the kidneys can lead to a build-up or metabolites, in case of repeated administration. The status of the condition was also elaborated for this group and a final visit was conducted; thereby, detecting the NOM. Patients in the control group were subjected to HbA1c measurement at the beginning and end of the study; they also had an initial farmacoterapeuticp with the pharmacotherapeutical record format, according to the DADER methodology.
Causes of NOM identified in the farmacoterrapeutico patients can be seen in Table 3.
The present study was conducted in order to understand the types of drug-related problems, and the negative outcomes associated seguiimento medications, that can be detected, prevented and solved in patients with chronic kidney disease, through pharmaceutical care practice.